Recombinant Human CD80 Protein

Recombinant human CD80 protein at the C-terminus.

Product Specifications

Background

The B-lymphocyte activation antigen B7-1 (referred to as B7), also known as CD80, is a member of cell surface immunoglobulin superfamily and is expressed on the surface of antigen-presenting cells including activated B cells, macrophages and dendritic cells. As costimulatory ligands, B7-1 which exists predominantly as dimer and the related protein B7-2, interact with the costimulatory receptors CD28 and cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) expressed on T cells, and thus constitute one of the dominant pathways that regulate T cell activation and tolerance, cytokine production, and the generation of CTL. The B7/CD28/CTLA4 pathway has the ability to both positively and negatively regulate immune responses. CD80 is thus regarded as promising therapeutic targets for autoimmune diseases and various carcinomas.

Synonyms

B7, B7-1, B7.1, BB1, CD28LG, CD28LG1, LAB7

Source

HEK293 Cells

Applications

SDS-PAGE

Endotoxin

<1.0EU per μg of the protein as determined by the LAL method

Purity

>85% by SDS-PAGE

Buffer

Lyophilized from sterile PBS, pH 7.4.

References & Citations

Greenfield EA, et al. (1998) CD28/B7 costimulation: a review. Crit Rev Immunol. 18 (5) : 389-418. Zang X, et al. (2007) The B7 family and cancer therapy: costimulation and coinhibition. Clin Cancer Res. 13 (18 Pt 1) : 5271-9. Mir MA, et al. (2008) Signaling through CD80: an approach for treating lymphomas. Expert Opin Ther Targets. 12 (8) : 969-79..